Biomarin Pharmaceutical Inc
NASDAQ: BMRN
$67.07
+$0.13 (+0.2%)
Closing Price on November 8, 2024
BMRN Articles
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Published:
Last Updated:
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
Published:
Last Updated:
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
Published:
Last Updated:
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Published:
Last Updated:
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Published:
Last Updated:
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
Published:
Last Updated:
BioMarin Pharmaceutical is ready to break above the $1 billion revenue barrier in 2016, a feat that marks a major hurdle for many biotech and emerging pharmaceutical companies.
Published:
Last Updated:
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Published:
Last Updated:
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
Published:
Last Updated:
A new research report from Jefferies focuses on a set of growth stocks for this week that have big upside. These four have some serious upside potential.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Published:
Last Updated:
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday, February 29, include Huntington Bancshares, Nucor, Orexigen Therapeutics, SanDisk, Square and VIVUS.
Published:
Last Updated:
Investors really took to BioMarin Pharmaceuticals stock and there was a favorable jump after the fourth-quarter earnings report.
Published:
Last Updated: